Singapore National Eye Centre, Duke-NUS Medical School, National University of Singapore, Singapore.
Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Clin Exp Ophthalmol. 2018 Jan;46(1):75-86. doi: 10.1111/ceo.12999. Epub 2017 Jun 21.
Diabetic macular oedema is the most common cause of diabetic retinopathy-induced vision loss. Efficacy of anti-vascular endothelial growth factor therapy in diabetic macular oedema has been demonstrated in randomized controlled trials. An Asian-specific guideline for diabetic macular oedema treatment is needed as patients in Asia tend to present with far more advanced disease than seen elsewhere in the world. Previous reviews of diabetic macular oedema management lacked a broader assessment of anti-vascular endothelial growth factor treatment choices and newer trials. Recent clinical trial data allow head-to-head comparisons between the different anti-vascular endothelial growth factor agents and treatment regimens. This review aims to summarize the clinical evidence related to various treatment regimens for clinicians, with a focus on anti-vascular endothelial growth factor therapies, and to provide guidance on the treatment of diabetic macular oedema in Asian patients.
糖尿病性黄斑水肿是糖尿病性视网膜病变导致视力丧失的最常见原因。随机对照试验已经证明了抗血管内皮生长因子治疗在糖尿病性黄斑水肿中的疗效。亚洲患者的疾病往往比世界其他地区更为严重，因此需要制定亚洲特有的糖尿病性黄斑水肿治疗指南。以前对糖尿病性黄斑水肿管理的综述缺乏对更广泛的抗血管内皮生长因子治疗选择和更新试验的评估。最近的临床试验数据允许对不同的抗血管内皮生长因子药物和治疗方案进行头对头比较。本综述旨在为临床医生总结与各种治疗方案相关的临床证据，重点是抗血管内皮生长因子治疗，并为亚洲患者的糖尿病性黄斑水肿治疗提供指导。
